Molecular Pharmacology: study shows effectiveness of topical anti-cytokine drug for inflammation

By Lisa Kerner

Charlotte, N.C., July 28 - Molecular Pharmacology (USA) Ltd. said that independent, replicated, multi-centered in-vitro studies demonstrated that the company's anti-cytokine drug, MPL-104, inhibits the secretion of TNF-alpha in inflammatory conditions, such as rheumatoid arthritis, lupus, Crohn's disease, psoriasis and ankylosing spondylitis.

"What makes MPL-104 such an exciting project is that it is directed at producing products that do not directly compete with the current markets leaders, and complement their functionality," president and chief executive officer Jeffrey Edwards said in a company news release.

MPL-104 can be formulated as a cream or serum and applied directly to the effected area or joint, without significantly altering systemic levels, officials said.

"We believe this will allow MPL-104 to be used to support and augment the total clinical efficacy of existing market leading drugs rather than be competitive to them," Edwards added.

Los Angeles-based Molecular Pharmacology develops analgesic, anti-inflammatory and anti-cytokine products.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.